Business Wire

International Energy Disputes Partner David Hesse Joins Hunton Andrews Kurth in London

22.8.2023 11:00:00 EEST | Business Wire | Press release

Share

David Hesse, an energy disputes attorney whose practice focuses on oil and gas litigation and arbitration matters with a strong emphasis on Africa has joined Hunton Andrews Kurth LLP as a partner in London.

Hesse advises states and national oil and gas companies on disputes, settlements, and upstream activities, as well as international tenders, refinery projects, farm-out agreements, and other contracts in the petroleum and petrochemical industries. His practice includes international commercial arbitration matters involving Anglophone and Francophone states and state entities in North, East, Central and West Africa.

Previously a partner with Clyde & Co., Hesse joins longtime colleague and collaborator Philip Mace as the newest additions to Hunton Andrews Kurth’s London-based energy team. Mace, who also recently joined the firm as a partner from Clyde & Co., is an experienced corporate lawyer whose practice is focused on energy and upstream oil and gas transactions.

“Robust global demand for large scale energy and infrastructure projects and the natural proliferation of disputes associated with those ventures continue to drive the need for a strong international arbitration and litigation practice,” said Tom Taylor, co-head of Hunton Andrews Kurth’s litigation team. “David is an outstanding lawyer whose experience and ability to navigate complex international disputes make him an ideal complement to the team.”

Hesse has extensive experience before international institutions including the International Chamber of Commerce (ICC) and International Centre for Settlement of Investment Disputes (ICSID). A selection of his notable representations prior to joining the firm include:

  • Advised the Government of Tanzania and the Tanzanian Electric Supply Company Limited (TANESCO) as co-lead international counsel with a local firm, in connection with related contract and treaty claims (ICSID) by Standard Chartered Bank.
  • Advised the Nigerian National Petroleum Corporation (NNPC) and supporting Nigerian counsel in connection with over $1 billion in claims by China National Offshore Oil Corporation (CNOOC) and South Atlantic Petroleum (SAPETRO) under a production sharing contract.
  • Advised the Government of Algeria and Sonatrach in connection with parallel proceedings (ICSID and UNCITRAL) by an oil and gas exploration company and an international shipping and logistics company for claims in excess of $8 billion relating to Algeria’s Windfall Profit Tax.
  • Advised the Government of Uganda and the Uganda Revenue Authority in connection with a $405 million claim by Heritage Oil (UNCITRAL) and a $473 million claim by Tullow Oil plc (ICSID) for recovery of capital gains tax under a production sharing agreement.
  • Advised ZCCM Investment Holdings PLC in connection with $2 billion in claims by Vedanta Resources Holdings Limited (UNCITRAL) relating to Konkola Copper Mines plc in Zambia.

“David’s practice complements our London-based projects and corporate offerings and reinforces our internationally recognized strength in the energy sector,” said Ferdinand Calice, managing partner of Hunton Andrews Kurth’s London office. “We are excited to welcome David to the firm.”

A recognized lawyer in Chambers Global and Legal 500, Hesse is also an Honorary Lecturer at the Centre for Energy, Petroleum and Mineral Law and Policy at the University of Dundee and a lecturer at the CWC School for Energy. He is a regular speaker at international arbitration and energy conferences, including Juris Conference, GAR Energy Disputes, and GAR Live.

Hesse received his undergraduate degree from the University of Cincinnati, his LLB (Maîtres) from the Universitie de Paris – La Sorbonne, and his LLM from Columbia Law School.

Hunton Andrews Kurth’s international arbitration and transnational litigation practice represents clients around the globe. We regularly handle investor-state arbitrations before the International Centre for Settlement of Investment Disputes (ICSID), and commercial arbitrations before the International Court of Arbitration of the International Chamber of Commerce (ICC); the London Court of International Arbitration (LCIA); the Singapore International Arbitration Centre (SIAC); the Permanent Court of Arbitration in The Hague; and the American Arbitration Association (AAA) and its international division, the International Centre for Dispute Resolution (ICDR). We also work with clients in multi-jurisdictional matters, working closely with counsel in local forums.

About Hunton Andrews Kurth LLP

With over 900 lawyers in the United States, Asia, Europe and the Middle East, Hunton Andrews Kurth LLP is a global firm that serves clients across a broad range of complex transactional, litigation and regulatory matters. The firm is known for its strength in the energy, financial services, real estate, and retail and consumer products industries, as well as its considerable experience in more than 100 distinct areas of practice, including privacy and cybersecurity, intellectual property, environmental, and mergers and acquisitions.

###

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

The PR Office
hak@theproffice.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release

Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release

Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release

Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye